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Defects in glycinergic inhibition result in a complex neuromotor disorder in humans known
as hyperekplexia (OMIM 149400) with similar phenotypes in rodents characterized by
an exaggerated startle reflex and hypertonia. Analogous to genetic defects in humans
single point mutations, microdeletions, or insertions in the Glra1 gene but also in the Glrb
gene underlie the pathology in mice. The mutations either localized in the α (spasmodic,
oscillator, cincinnati, Nmf11) or the β (spastic) subunit of the glycine receptor (GlyR) are
much less tolerated in mice than in humans, leaving the question for the existence
of different regulatory elements of the pathomechanisms in humans and rodents. In
addition to the spontaneous mutations, new insights into understanding of the regulatory
pathways in hyperekplexia or glycine encephalopathy arose from the constantly increasing
number of knock-out as well as knock-in mutants of GlyRs. Over the last five years, various
efforts using in vivo whole cell recordings provided a detailed analysis of the kinetic
parameters underlying glycinergic dysfunction. Presynaptic compensation as well as
postsynaptic compensatory mechanisms in these mice by other GlyR subunits or GABAA
receptors, and the role of extra-synaptic GlyRs is still a matter of debate. A recent study
on the mouse mutant oscillator displayed a novel aspect for compensation of functionality
by complementation of receptor domains that fold independently. This review focuses on
defects in glycinergic neurotransmission in mice discussed with the background of human
hyperekplexia en route to strategies of compensation.
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INTRODUCTION
Synaptic inhibition is mediated by activation of glycine receptors
(GlyRs) and γ-aminobutyric acid (GABA) receptors. GlyRsmedi-
ate fast inhibitory neurotransmission in the adult spinal cord,
which is important for motor control. Functional impairments
of spinal GlyRs or associated proteins lead to the rare neuromo-
tor disorder hyperekplexia (Startle disease, Stiff Baby Syndrome,
OMIM #149400) in humans with similar phenotypes in rodents.
In hyperekplexia, affected neonates exhibit exaggerated startle
responses and muscle stiffness following an unexpected acous-
tic noise or a tactile stimulus, which may result in fatal apnea.
During early childhood the muscle tone returns to normal lev-
els, but startling persists into the adulthood (Andermann et al.,
1980; Shiang et al., 1993; Becker et al., 2008). Predominantly,
single pointmutations in theGLRA1 gene encoding the GlyR sub-
unit α1 (GlyRα1) underlie the pathology in humans. Analogous
genetic defects have been observed in mice. The mutations are
either localized in the α (spasmodic, oscillator, cincinnati, Nmf11)
or the β (spastic) subunit of the GlyR. Recently, other animal
models of glycinergic dysfunction have been reported in zebrafish
(bandoneon, shocked) and cow (CMD2). Among the mouse muta-
tions, spasmodic, spastic, oscillator, and cincinnati harbor spon-
taneous mutations, the Nmf11 mouse mutant instead results
from chemical induction (Buckwalter et al., 1994; Kingsmore
et al., 1994; Mulhardt et al., 1994; Ryan et al., 1994; Holland
et al., 2006; Traka et al., 2006). These mouse models of GlyR
dysfunction have served as excellent systems for studying the
pathomechanisms of the corresponding human neurological dis-
ease. It turned out, however, that the phenotype in mice is much
more severe than in humans, e.g., a functional null allele is
lethal in mice (oscillator) but not in humans, arguing for dif-
ferent compensatory mechanisms in both organisms (Tsai et al.,
2004; Becker et al., 2006). The response to clonazepam treatment
is another example for differences in compensatory effects. In
patients, startle attacks are reduced and a normal muscle tone
could be reached following clonazepam treatment. The benzo-
diazepine clonazepam enhances GABA-gated chloride currents
upon binding to GABAA receptors exhibiting an up-regulation
of GABAergic neurotransmission as one possible compensatory
mechanism at least in humans. In contrast, no similar mecha-
nism seems to exist in mice after clonazepam treatment. Here,
background effects as well as the existence of other so far uniden-
tified regulatory proteins or modulators of the disease are under
discussion (Buckwalter et al., 1994; Becker et al., 2006; Molon
et al., 2006). In the two mouse models spastic and oscillator
a functional rescue has been shown using different approaches
in vitro and in vivo. With a transgenic approach in the mouse
mutant spastic the phenotype was rescued by restoring the β
expression levels toward sufficient amounts for proper function-
ing of glycinergic synapses (Hartenstein et al., 1996). Using a
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complementation strategy, α1 levels came up in spinal cord neu-
rons isolated from homozygous oscillator mice (Villmann et al.,
2009a).
This review will discuss the various mouse models of glyciner-
gic disinhibition to understand the pathomechanisms and regu-
latory pathways of the neuromotor disorder hyperekplexia. With
the help of knock-out, and knock-in studies of GlyR subunits,
including novel strategies such as rescue experiments new per-
spectives of pre- or postsynaptic compensation will be elaborated.
GLYCINERGIC SYNAPSES AND NEUROMOTOR BEHAVIOR
Glycinergic neurons appear during development in the vertebrate
central nervous system (CNS) from embryonic day 12.5 (E12.5)
on in the somata of ventral horn cells in the spinal cord, fol-
lowed by cells in the dorsal horn one day later (Allain et al.,
2006; Chalphin and Saha, 2010). Prominent GlyR immunoreac-
tivity has been also detected in the ventral and dorsal horns of
the spinal cord, the spinal trigeminal nuclear complex, the dor-
sal motor nucleus of the vagus nerve, and the hypoglossal nucleus
(Rampon et al., 1996; Baer et al., 2009). Further GlyR expression
in the adult CNS has been determined in midbrain, caudal and
rostral pons, rostral medulla oblongata, retina, different nuclei of
the forebrain, and the cochlea (Greferath et al., 1994; Baer et al.,
2003; Waldvogel et al., 2007; Dlugaiczyk et al., 2008).
In early stages of development GABAergic transmission pre-
dominates over glycinergic transmission. At this time both neu-
rotransmitters depolarize neurons (Gonzalez-Forero and Alvarez,
2005; Scain et al., 2010). In the neonatal brain many inhibitory
synapses initially are mixed GABAergic and glycinergic, which
changes during CNS maturation between P5 and P14 depending
on the CNS area (Jonas et al., 1998; Kotak et al., 1998). The switch
toward glycinergic transmission has been observed inmany spinal
and brainstem synapses, e.g., in the lumbar spinal cord and in the
lateral superior olive of young rodents (Gao et al., 2001; Nabekura
et al., 2004; Muller et al., 2006; Scain et al., 2010). But there are
also regions in which GABAergic neurotransmission dominates in
the developing brain for example in the collicular neurons (Meier
et al., 2002).
Important in the maturation of ventral inhibitory synapses
are the developing interneurons (e.g., IaIN, V2b, Renshaw cells),
which possess diverse roles in shaping locomotor patterns. These
interneurons are assigned to enable reciprocal (Ia inhibitory
neurons), feedback (Renshaw cells), and feed-forward (presy-
naptic sensory) inhibition (Figure 1) (Siembab et al., 2010).
Compared to other ventral interneurons, Renshaw cells become
greatly potentiated inhibitory synaptic inputs during postna-
tal development as a consequence of functional adaptation.
Renshaw cell-mediated recurrent inhibition allows the control of
the dynamic behavior of motoneuron (MN) firing (Gonzalez-
Forero and Alvarez, 2005; Alvarez and Fyffe, 2007). Neuromotor
behavior is fine-tuned by recurrent inhibition, which involves the
action of GlyRs binding the inhibitory neurotransmitter glycine.
The activation of GlyRs leads to chloride influx and therefore
hyperpolarization of the motoneuronal membrane restoring the
balance between excitation and inhibition (Figure 1). This feed-
back circuit emphasizes the importance of glycinergic inhibition
in the adult spinal cord and brainstem.
Disturbances in GlyR inhibition due to a single amino acid
substitution in one of the GlyR subunits give rise to a dif-
ferent MN-firing pattern associated with overactivation of the
muscle and muscle stiffness. Such symptoms are observed in
patients suffering from hyperekplexia. These patients carry a
mutant allele with either a single nucleotide polymorphism (SNP)
leading to an amino acid exchange at the protein level, dele-
tions of various exons or nonsense mutations (Harvey et al.,
2008). Dominant mutations have been shown to result in differ-
ences in physiological properties of the ion channel itself. The
majority is localized within the ion channel domain itself and
adjacent loop structures (Lynch et al., 1997). Recessive mutations
showed up with a disturbed biogenesis with regard to traffick-
ing and accumulation in the endoplasmic reticulum. In addition,
the stability of these mutants is highly affected (Villmann et al.,
2009b). In homozygous mutant mice point mutations within
the Glra1 and the Glrb gene result in similar phenotypes with
typical startle attacks, massive tremor and rigidity from post-
natal day 15 on. This has been shown for spontaneous mouse
mutants as well as for knock-in animals carrying point muta-
tions that were identified in human patients (Findlay et al., 2003;
Borghese et al., 2012). Between postnatal days 15 and 21 the dis-
ease is highly progressive and lethal for the majority of mutants.
The lethal phenotype has been noted for mutations in the α1
and β subunit, both of which are part of the adult receptor
complex. In contrast, α2 or α3 knockout animals do show a
rather mild phenotype (Harvey et al., 2004; Young-Pearse et al.,
2006). Thus, compensatory mechanisms get rather initialized by
a complete loss of protein function than following the expres-
sion of misfolded receptor proteins accumulating in the cell,
respectively.
GLYCINE RECEPTORS—LIGAND-GATED CHLORIDE
CHANNELS
GlyRs are members of the superfamily of Cys-loop receptors
(CLRs) as the nicotinic acetylcholine receptors, the 5HT3 recep-
tor, and GABAA/C receptors (Lynch, 2009). The overall topology
of a single subunit with a conserved disulphide bridge in the
N-terminus is common to all members of the CLR family (Lynch,
2004). Characteristic features are a short C-terminus and a highly
structured N-terminus, which exhibits a high homology to the
acetylcholine binding protein of the pond snail Lymnea stag-
nalis, whose structure was solved by X-ray crystallography with
a resolution of 2.7 Å (Brejc et al., 2001). The N-terminal domain
displays an immunoglobuline-like structure characterized by a
short α-helical domain in the far N-terminus followed by 10 β-
sheets. Meanwhile, the X-ray structure of other members of the
CLR superfamily has been solved, e.g., GLIC and ELIC (Hilf
and Dutzler, 2008, 2009; Bocquet et al., 2009), two members
of prokaryotic origin, and the GluCl, a glutamate-gated chlo-
ride channel from C. elegans with 34% protein identity to the
GlyR structure (Hibbs and Gouaux, 2011). Furthermore, each
subunit comprises 4 transmembrane domains (TMs) connected
by intra- or extracellular loop structures. TM2 forms the ion
channel pore. The highest diversity among GlyR subunits and
also among different families of CLRs lies in the large TM3-4
loop. This loop is thought to be important for biogenesis and
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FIGURE 1 | Nerve-muscle circuit. (A) Following an acoustic signal or a
tactile stimulus, sensory neurons (red), which are located in dorsal root
ganglia, release glutamate that binds to appropriate receptors localized at the
motoneuronal membrane (yellow), thereby leading to membrane
depolarization. The motoneuron fires action potentials toward the
neuromotor endplate where the signal is transmitted again via an excitatory
(nicotinic) neurotransmitter acetylcholine. The efficiency of the system is
enabled by the action of glycine receptors. Inhibitory interneurons (orange,
IaIN, or Renshaw cells) in the spinal cord get activated by either acetylcholine
released from collateral axons of the motoneuron or glutamate released from
primary afferents, form inhibitory synapses with the membrane of
motoneurons. Renshaw cells release glycine that binds to the GlyRs localized
at the motoneuronal membrane leading to hyperpolarization of the
membrane. Thus, functional GlyRs lead via the feedback control loop to only
that amount of acetylcholine release, which is sufficient to reach the
threshold for an action potential that propagates along the muscle fiber.
(B) GlyRs are localized at the postsynaptic membrane in a pentameric
receptor configuration of 2α and 3β subunits. The intracellular scaffold protein
gephyrin clusters the GlyRs at the membrane thereby forming a hexagonal
lattice structure. The activation of voltage-gated calcium channels present in
the presynapse lead to calcium influx. As a consequence, mixed
GABA/glycine vesicles fuse to the presynaptic membrane and release their
content into the synaptic cleft. Following binding of glycine to the GlyR, a
conformational change leads to ion channel opening and chloride ion influx.
posttranslational modifications (Sadtler et al., 2003; Breitinger
et al., 2009; Villmann et al., 2009a).
Upon agonist binding toward the ligand-binding cavity (Brejc
et al., 2001; Unwin, 2005) an intrinsic chloride channel opens.
The structural data have shown that amino acids from N-
terminal loop structures, loops A, B, and C from one subunit
(plus side or principal face) together with loops D, E, and
F from another subunit (minus side or complementary face)
form the ligand binding cavity between different subunits. The
adult receptor channel complex consists of 5 subunits assembling
into a rosette-like heteropentamer of two α and three β sub-
units both of which are involved in ligand binding (Grudzinska
et al., 2005; Dutertre et al., 2012). The opening of the GlyR ion
channel pore follows a ligand-induced (starting with the high-
est affinity: glycine > β-alanine > taurine) transition process
(Lynch, 2004).
GlyR SUBUNIT DIVERSITY AND DEVELOPMENTAL
REGULATION
At present four GlyRα-subunits encoded by different genes are
known, as well as one single β-subunit. Alternative splicing of the
α subunits as well as the β-subunit results in further diversity of
GlyR complexes (Malosio et al., 1991a; Kuhse et al., 1993; Nikolic
et al., 1998; Harvey et al., 2004; Heinze et al., 2007; Oertel et al.,
2007).
GlyRα1 exists in two splice variants (α1ins described for rat,
mice, and humans) with one harboring additional 8 amino acids
in the TM3-4 loop (Malosio et al., 1991a; Strausberg et al.,
2002). Both α1 variants do not differ in physiological charac-
teristics in transfected cell lines. The α1 subunit mRNA in rats
is first detectable at postnatal day 5 and increases constantly
into the adulthood (Malosio et al., 1991b; Sato et al., 1991).
The expression of the α1 is most prominent in brain nuclei and
spinal cord; some immunoreactivity was observed in the supe-
rior and inferior folliculi and regions of the hypothalamus and
in the thalamus (Sato et al., 1991). The mRNA of α2 has been
detected first around embryonic day E15 and decreased after
birth (Malosio et al., 1991b). Originally, a developmental switch
from a neonatal isoform GlyRN composed of α2 homomers to
the adult isoform (GlyRA) α1β heteromers was postulated. This
switch was proposed to be complete by postnatal day 20. For
GlyRα2 also two alternative splice variants with alternative exons
3 have been described, either exon 3A or 3B. The resulting pro-
teins differ in only two amino acid residues in the extracellular
N-terminal part of the receptor (Kuhse et al., 1991). Recent find-
ings suggest that the α2 expression persists into adulthood in
retina, cerebellum, and auditory brain stem (Piechotta et al., 2001;
Young and Cepko, 2004; Heinze et al., 2007; Nobles et al., 2012).
GlyR3α also exists in two splice variants, differing in a 15 amino
acid insertion in the TM3-4 loop (α3L and α3K). Both variants
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show similar distribution which is comparable to the α1 sub-
unit, but with significantly less intensity. In contrast to the α1
splice isoforms α3L and α3K differ in ion channel properties,
e.g., in desensitization behavior with α3K forming fast desen-
sitizing channels and α3L representing the slower desensitizing
receptor complexes (Nikolic et al., 1998). In addition, RNA edit-
ing has been shown to increase the diversity of GlyRα3 (Meier
et al., 2005). The α3 variant P185L emerges from cytidine 554
deamination (C554U). Neurons harboring α3P185L assign high
glycine potency and non-desensitized receptors, which are pre-
requisites for tonic inhibition (Stell and Mody, 2002). The α4
subunit has been found in the adult mouse retina where it clus-
ters together with synaptic markers such as bassoon or gephyrin
(Heinze et al., 2007). Furthermore, GlyRα4 transcripts have been
detected in the white matter tract of the developing spinal cord
from mice. The avian α4 mRNA was also found in dorsal root
ganglia and genital ridge. Although the function of GlyRα4 at its
sites of expression is still unknown, homomeric α4 receptors are
able to form fully functional glycine-gated Cl− channels in vitro
that can be antagonized with strychnine (Harvey et al., 2000).
GlyRβ transcripts are widely expressed also in organs where
no α subunit is present. The β expression starts around E14 but
increases rapidly after birth (Malosio et al., 1991b). The β sub-
unit is part of the adult GlyR complex, which is composed of 2α
and 3β subunits (Grudzinska et al., 2005) with α1β representing
the major form of heteromers. The function of the β subunits in
tissues lacking GlyRα subunits is still enigmatic. Synaptic GlyRs
are clustered by gephyrin via an interaction motif in the TM3-4
loop of the β subunits. Gephyrin is a scaffolding protein in the
plasma membrane that mediates mobility of GlyRs and thereby
contributes to the plasticity of inhibitory synapses (Fritschy et al.,
2008; Calamai et al., 2009).
SPONTANEOUSMOUSE MUTANTS OF THE Glra1 AND Glrb
GENE
To date five spontaneous and recessively inherited mutations in
mice serve as models for human hyperekplexia. Four mutations
occurred without any manipulation, such as spasmodic (spd),
oscillator (spdot), cincinnati, and spastic (spa) (Figure 2, Table 1).
The fifth spontaneous mutation nmf11 was induced by ENU (N-
ethyl-N-nitrosourea), which is a powerful chemical mutagen that
offers the possibility to induce point mutations genome-wide
with a high frequency (Balling, 2001). This part will discuss the
spontaneous mutations with regard to symptoms and progres-
sion of the disease, the genetic location of the mutations, and
the resulting failure at the protein level being responsible for the
phenotype of affected mice.
THE SPASMODIC MOUSE MUTANT—AMISSENSE MUTATION
Homozygous spd/spd mice develop hyperekplexia like pheno-
types characterized by an exaggerated acoustic startle reflex, high
tremor, and an impaired righting reflex. Symptoms start in the
third week after birth. Before this period, spd/spd mice are phe-
notypically normal and are indistinguishable from heterozygous
or wild type siblings. No progression within the symptoms can
be observed with age and homozygous mutants do have a normal
life expectancy (Lane et al., 1987).
FIGURE 2 | Overview about GlyR mouse mutants from DNA level to
the protein level. The Glra1 gene comprises 9 exons (Glrb 10 exons). Left
column: SNPs are indicated by numbers. The C to T transition at position
159 in spasmodic mice is shown. The microdeletion in exon 8 of the
oscillator mouse is listed by an insertion. In addition, exon 9 harbors an
alternative splicing cassette (ASC) responsible for the generation of the two
different mRNAs in the adult organism. For the cininnati mouse the intronic
internal repeats (GGGGC) responsible for exon 5 duplication are shown. In
the Nmf mutant a C to A transition in exon 2 of the Glra1 gene was
demonstrated. The insertion of the LINE1 element into intron 6 of the Glrb
gene is marked. Aberrant splicing is indicated by dotted lines. Middle
column: represents the different mRNAs, which are formed. SNPs are
marked with numbers below the appropriate exon, e.g., spd C159T. Two
mRNAs are generated in oscillator due to alternative use of the splice
acceptor site in exon 9. Usage of this site leads to exclusion of the ASC
(24bp), non-usage generates an mRNA with the 24bp ASC. Cincinnati
harbors the exon 5 duplication with generation of a premature stop codon.
The SNP C138A in the Nmf11mouse is marked. As a consequence of the
LINE1 insertion into intron 6 of the Glrb gene, abberant splicing with exon 6
and exon 5/6 exclusion are observed. Right column refers to the GlyR
proteins. In spasmodic mice a GlyR harboring the A52S mutation
decreasing glycine affinity is marked. The premature STOP codons in
oscillator and cincinnati result in no expression of GlyRα1. The single amino
acid exchange N46K in the Nmf mutant is due to the C to A transition in
exon 2 of the Glra1 gene. Abberant splicing of Glrb in the spastic mouse
model results in a highly reduced number of full-length GlyRβ.
A point mutation in the Glra1 gene at chromosome 11,
which leads to a change of an alanine into a serine at posi-
tion 52 of the mature polypeptide sequence, has been found as
the genetic reason for the phenotype in spasmodic mice (Ryan
et al., 1994). The spd locus on chromosome 11 is linked by
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synteny homology to the human chromosomal region 5q21–q31,
where the α1 subunit gene has been mapped (Shiang et al.,
1993). A further but silent mutation was found at position
198 (Figure 2, Table 1) (Matzenbach et al., 1994; Saul et al.,
1994). Although these animals develop a phenotype, the loca-
tion of the protein seems not to be affected. The X-ray structure
solved from homologous CLR protein AchBP defined various
loop structures within the N-terminal domain of the protein that
are involved in ligand binding (Brejc et al., 2001). The amino
acid position A52S does not lie within this interface between
two adjacent subunits, neither at the plus nor at the minus
site of ligand binding. A52S only flanks the proposed assem-
bly boxes and seems not to impair the overall protein content
of GlyRα1 which is indistinguishable between wild type and
homozygous spasmodic mice (Saul et al., 1994). In these chan-
nels the binding affinity of the agonists glycine, β-alanine and
taurine is altered with a rightward shift in the glycine EC50
(Figure 3) (Saul et al., 1994; Graham et al., 2006, 2011). Excised
patches from spasmodic superficial dorsal horn (SFDH) neurons
show no single channel openings at low glycine concentration
and only a few openings to high glycine concentrations com-
pared to wild type neurons with multiple channel openings at
the same glycine concentration. A detailed characterization of
another point mutation at position 52 (A52C) within β1–β2 loop
suggests that the microenvironment of A52 is responsible for
different conformations of the β1–β2 loop and thereby ham-
per the agonist glycine from binding to the subunit interface
(Pless and Lynch, 2009).
THE OSCILLATOR MOUSE—A FRAMESHIFT MUTATION LEADING TO
COMPLETE LOSS OF FUNCTION
Homozygous oscillator mice represent a null mutation accom-
panied by a lethal phenotype. In contrast to spasmodic mice,
oscillator mice always die within 3 weeks of age. Their neuro-
muscular symptoms like fine tremor and muscle spasm start at
the age of 2 weeks and worsen progressively. The symptoms of
FIGURE 3 | Agonist sensitivity in spasmodic GlyRs recorded from
superficial dorsal horn neurons [from Graham et al. (2011)].
(A) Decreased glycine-evoked currents recorded in excised membrane
patches from spasmodic SDH neurons compared to wild type using the
same glycine concentration. (B) Concentration–response plots for wild type
and spasmodic patches (n = 8 and 15, respectively) are shown. The
concentration–response curve is shifted to rightwards for spasmodic
patches. Inset summarizes EC50 values for spasmodic and wild type
receptors. (C) Representative glycine responses for wild-type (left) and
spasmodic (right) patches to bath application of low and high glycine
concentrations. In wild type patches brief single channel openings are evoked
by low glycine concentrations and high concentrations evoke multiple
channel openings (inset shows channel openings on expanded time scale). In
spasmodic patches no single channel events are observed at low glycine
concentrations. At high glycine only a few openings are observed. (D) Plots
summarizing results from experiments in (C). Only 3/13 spasmodic patches
responded at low glycine concentration, demonstrating again the lower
affinity of this mutant to the agonist compared to wild type. ∗P < 0.05.
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this phenotype are highly comparable to strychnine poisoning in
humans.
The genetic cause is also a mutation in the Glra1 gene
(Buckwalter et al., 1994). The oscillator allele Glra1spd−ot exhibits
a microdeletion of 9 bp plus a microinsertion of 2 bp resulting in
a frameshift. Depending on differential use of two splice acceptor
sites in exon 9 of Glra1 (Figure 2, Table 1), two α1 polypeptide
mutants are encoded, both of which lack TM4 (Malosio et al.,
1991a). Inclusion of the alternative splice cassette resulted in a
premature STOP codon within this 8 amino acid cassette thereby
comprising a truncated α1 variant (spdot-trc). The long splice
variant, spdot-elg, was generated from an exclusion of the alterna-
tive 24 bp and encodes 150 missense residues at the C-terminus
(Villmann et al., 2009a).
Due to the frameshift motifs important for receptor biogene-
sis and trafficking are destroyed (Sadtler et al., 2003). In the CNS
of homozygous oscillator mutants, a complete loss of functional
GlyRα1 protein neither spdot-trc nor spdot-elg was observed, char-
acterizing oscillator as a functional null mutation of the Glra1
gene (Kling et al., 1997). Using an independent domain approach
in vitro, we were able show that the truncated GlyRα1 subunit
variant spdot-trc can efficiently be rescued by coexpression with
an independent C-terminal tail domain representing the lack-
ing GlyRα1 protein proportion (most of the TM3-4 loop, TM4,
and the C-terminus). This functional complementation of GlyRs
demonstrated the importance of the TM3-4 loop for biogene-
sis, clustering and pharmacological properties as demonstrated
in transfected HEK293 cells and spinal cord neurons from ot/ot
animals (Figure 4). Such reconstruction of a functional ligand-
gated ion channel by independent folding domains resembles
novel directions for compensatory mechanisms using gene ther-
apeutical approaches (Villmann et al., 2009a). In vivo recordings
in hypoglossal MNs of homozygous oscillator mice demonstrated
a dramatic decrease in frequency and amplitude of mIPSCs
together with a much slower decay time compared to heterozy-
gous control mice. The fact of any glycinergic mIPSCs in the
functionally null mutant ot/ot suggests a compensation via α2, α3,
or α4 subunits expressed in MNs; however, these at distal den-
dritic locations expressed receptor clusters are not sufficient to
sustain life (Graham et al., 2006).
THE CINCINNATI MOUSE—ANOTHER FRAMESHIFT MUTATION
Cincinnati is a spontaneous mutation in the Glra1 gene with
a similar phenotype to the other spontaneous mouse mutants
already described. At 2 weeks of age, affected mice exhibit
impaired righting reflex and tremor. This progress worsens till
their death within 3 weeks of age as observed for oscillator mice
(Figure 2, Table 1) (Holland et al., 2006). The mutant was rec-
ognized by the generation of multiple affected offsprings from
one mating. Further breedings with obligate heterozygote ani-
mals with the strain C3H/HeCr1BR showedmoremutants among
the F1 generation. Further randomly crosses with the mentioned
strain showed a recessively inherited autosomal inheritance.
Analysis of the genomic sequence did not show any insertions
of LINE or SINE (long or short interspersed nuclear elements)
elements as seen in spastic. But in introns 4 and 5 of Glra1 gene a
perfectly aligned repeat of the pentamer GGGGC was found. Very
short direct repeats in adjacent introns are able to mediate exon
duplication (Chen et al., 2005). The cincinnati mouse, indeed,
shows two tandem copies of the 83 bp exon 5. This exon dupli-
cation in Glra1 transcript results in a frameshift mutation with
a novel generated premature stop codon (F159X) followed by a
loss of GlyRα1 function comparable to the oscillator mutant. The
predicted protein lacks the C-terminal 271 residues of the GlyRα1
protein. Thus, exon duplication is a common process contribut-
ing significantly to the evolution of functional complexity in the
genome. Large deletions have also been observed in humans suf-
fering from hyperekplexia with a deletion of exons 1–7 (Becker
et al., 2006). Here, a complete loss of GlyRα1 is, however, much
better tolerated by the human organism arguing for different
compensation routes in humans compared to mice.
THE SPASTIC MOUSE MUTANT—ANABERRANT SPLICING MUTATION
Homozygous spa mice manifest at the postnatal age of 2 weeks
hyperekplexia-like severe neuromuscular symptoms, such as
exaggerated startle response, rapid tremor, myoclonus, rigidity,
and impaired righting reflex (Figure 2, Table 1) (Becker, 1990;
Kingsmore et al., 1994; Mulhardt et al., 1994).
An insertion of a repetitive LINE1 element in intron 6 of the
Glrb gene at chromosome 3 is the genetic reason for the neuromo-
tor phenotype in spa/spa mice. This mutation leads to deficient
mRNA splicing with functional β mRNA levels being decreased
to approximately 10% (Kingsmore et al., 1994; Mulhardt et al.,
1994). The mouse GlyR β subunit is encoded on chromosome 3q.
The β subunit of the GlyR is known to be an important struc-
tural component of the pentameric GlyR complex for its synaptic
location. Clustering of GlyRs at postsynaptic sites is enabled via
an interaction of a binding motif in the intracellular TM3-4 loop
of the β subunit to the scaffolding protein gephyrin. Moreover,
recently it has been shown that GlyRβ is also involved in ligand
binding, yet with low affinity (Grudzinska et al., 2005; Dutertre
et al., 2012). It has been reported that within litters mild as well
as severe phenotypes of homozygous spa/spa animals exist. A
different level of mRNA expression has been ruled out (Molon
et al., 2006). Following a differentiation of spa/spa animals into
three groups, mice with early stage (M.e.s.), mice with recovery
stage (M.r.s.), and severe phenotype (Sev), a compensatory effect
with an up-regulation of the GlyRα1mRNA has only been found
for older recovered mice (M.r.s.) concomitantly with a higher
GlyRα1 protein amount. In contrast, an up-regulation of the fetal
glycine receptor GlyRα2 could never been observed. The higher
amount of GlyRα1 protein can be one possible mechanism of
compensation of GlyRβ loss accompanied by functional recovery
observed in these mice, respectively. Furthermore, in mice with
a severe phenotype apoptosis together with the loss of glyciner-
gic interneurons in the ventral horn of the spinal cord have been
found followed by a dramatic loss of MNs. Last could explain
the paralysis and early death of these homozogous spa/spa pop-
ulation (Molon et al., 2006). Functional data from recordings in
brainstem slices containing the hypoglossal nuclei further support
this observation. Graham et al. have demonstrated that in spa/spa
mice glycinergic inhibition in hypoglossal MNs is decreased with-
out a dramatic change in receptor kinetics; however, whole-cell
GlyR currents were picrotoxin sensitive. Picrotoxin-sensitivity did
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FIGURE 4 | GlyRs re-constituted from independent folding domains
(modified from Villmann et al., 2009a). Rescue of function experiments
of spdot constructs compared with truncated α1 variants. Using whole-cell
recordings from transfected HEK293 cells, maximal glycine (gly)-gated
currents were determined with 3mM glycine: (A) α1A wt; (B) α1A wt
blocked with strychnine (stry); (C) α1A-trc, spdot -trc and spdot -elg when
expressed alone generated non-functional channels; (D) α1A-trc plus
myc–α1–iD–TM4 restored functionality and was antagonized with strychnine
(E); (F) spdot -trc plus myc–α1–iD–TM4 restored functional GlyRs but with
less efficiency compared to α1-trc; (G) spdot -elg plus myc–α1–iD–TM4
never generated functional channels. (H) Spinal cord neurons were infected
with C-terminal domain constructs encoded on a pAAV vector. Comparison
of infected (DIV21; bottom) and uninfected spinal cord neurons isolated
from either homozygous wild type (+/+) or oscillator (ot/ot) mice (DIV21
uninfected). The α1-antibody Mab2b recognizes only the α1 variant,
whereas pan-α recognizes all GlyRα variants. After infection with different
constructs (myc–α1–iD–TM4, pc–α1–iD–TM4-myc, or α1–iD–TM4) infected
neurons expressed endogenous GlyRα1 protein (bottom 3 panels, right
pictures, depicted in red) that co-localized (merged pictures) with the
appropriate C-terminal domains.
not result from homomeric GlyRα2 or GABAergic compensation
as upregulation of GlyRα2 was not observed and all measure-
ments have been performed in the presence of GABAA receptor
antagonist bicuculline. Thus, at least a distinct proportion of
GlyRs in spastic mice results from homomeric GlyRα1 recep-
tors. A synaptic location of homomeric α1 clusters was excluded
since GlyR-mediated evoked IPSCSs from spa/spa and wild type
animals showed the same picrotoxin sensitivity (Graham et al.,
2006). Furthermore, a decrease in GlyR number at synaptic sites
has been shown by different approaches, such as immunohisto-
chemical or biochemical stainings (Becker et al., 1986; Callister
et al., 1999). The described examinations so far only concentrated
on the postsynaptic site of the glycinergic synapse. Muller et al.
considered presynaptic effects in spa/spa mice. In the developing
hypoglossal nucleus of spastic mice glycinergic presynaptic ter-
minals decreased during the first two postnatal weeks whereas
GABAergic terminals increased. In contrast, glycinergic termi-
nals increase in inhibitory synapses in wild type mice during the
same developmental period. Although this presynaptic adapta-
tion of neurotransmitter content in response to the decrease of
GlyRβ at the postsynaptic membrane demonstrates a crosstalk
between pre- and postsynaptic elements in spastic mice, the
observed GABAergic upregulation was not sufficient to compen-
sate for defective glycinergic neurotransmission (Muller et al.,
2008).
Interestingly, the reduced expression of GlyRβ at the protein
level can be rescued by transgenic expression of an exogenous
rat GlyRβ minigene. This minigene construct contained a rat
GlyRβ cDNA, which was cloned into an expression vector suit-
able for driving brain-specific expression under the control of the
rat neuron-specific enolase promoter (NSE). With this minigene
a higher protein expression (approximately 25%) of full-length
Frontiers in Molecular Neuroscience www.frontiersin.org October 2012 | Volume 5 | Article 98 | 8
Schaefer et al. GlyR mouse models of hyperekplexia
GlyRβ could be reached and a rescue of the symptoms has been
observed (Hartenstein et al., 1996).
Homozygous mice (spa/spa) with a C57BL/6J (B6) back-
ground have strong symptoms and die at about 3 weeks
after birth, while spa/spa animals of the backcross strain
F1(C57BL/6J × C3H/HeJ) × C57BL/6J (C3H) show milder
symptoms and mostly survive the critical age (von Wegerer et al.,
2003). With ageing, these animals develop joint contractures
and a vertebral arthopathy (Ziv et al., 1984), but their anatom-
ical structures in spinal cord, CNS, or muscles are not altered
or changed. The C3H/HeJ mouse strain seems to harbor an
additional splicing factor or another modifying candidate gene,
which enables spa/spa mice to sustain life. Very recently, a short
nucleotide polymorphism (SNP) was localized in Glrb exon 6 at
an exonic splicing enhancer (ESE) site, regulating exon skipping
in Glrb. This ESE site is a binding site of the essential splicing
regulatory protein SRSF1. Furthermore, the 5′ and 3′ UTR of
the LINE1 were shown to be critical determinants for exon skip-
ping, indicating that the LINE1 represents an efficient modifier of
endogenous splicing phenotypes (Becker et al., 2012).
THE Nmf11 MUTATION—AN ENU INDUCED POINT MUTATION
Nmf11 homozygous mice show an oscillator-like phenotype with
an early death within 3 weeks after birth. In contrast to oscilla-
tor, the Nmf11 mutation was chemically induced by a powerful
chemical mutagen N-ethyl-N-nitrosourea (ENU). ENU is used to
induce point mutations genome-wide with a high frequency. The
Nmf11mutation inmice courses a C-to-A transition of nucleotide
138, which results in the N46K substitution in the long extra-
cellular N-terminal ligand-binding domain of the Glra1 mature
protein (Figure 2,Table 1) (Traka et al., 2006). Themutation does
not affect Glra1 mRNA and protein levels nor does it block the
correct membrane targeting of the protein given that substan-
tial amounts of the receptor were detected at synaptic sites of
Nmf11 homozygotes. The mechanism by which the Nmf11 muta-
tion impairs GlyR function is currently unknown. The mode of
actions could either be due to differences in ligand binding or
gating, respectively (Traka et al., 2006). Disturbances in recep-
tor assembly seemed to be unfavorable, as well as a defect in
oligomerization. The latter has been shown to be dependent on
TM4 and aromatic residues within the other TMs (Haeger et al.,
2010).
KNOCK-OUT GlyR MOUSE MUTANTS
A commonly used strategy to investigate the physiological role
and significance of proteins is the generation of correspond-
ing knock-out animals. Thereby the animal becomes deficient
of the desired protein within either specific cell types or organs
(conditional knock-out) or throughout the whole organism.
Concerning the glycinergic system of inhibitory neurotransmis-
sion a variety of knock-out mice exist displaying deficiency of
either the α2 or α3 subunit of the inhibitory GlyR. Naturally
occuring mutations of the murine GlyRα1 subunit, as in the
spontaneous mouse mutant oscillator, lead to loss of the respec-
tive protein, thus resembling the knock-out α1 situation (Kling
et al., 1997). The absence of GlyRα1 exhibits the most severe phe-
notype since it is the subunit that is primarily responsible for
glycinergic inhibition in the adult animals. It is widely expressed
in brain stem and spinal cord, where the neuronal control of
excitability is enabled by synaptic α1β heteromeric GlyR clus-
ters. In contrast, deletions of either the GlyRα2 or α3 subunits
resulted in mild phenotypes with no major morphological or
molecular disturbances compared to oscillator mice (Harvey et al.,
2004; Young-Pearse et al., 2006). Both knock-out mice will be
discussed in more detail with regard to possible compensatory
mechanisms.
Glra2 KNOCK-OUTMICE
The Glra2 gene encodes the α2 subunit of the inhibitory GlyR.
Two different variants α2A and α2B are known to be gener-
ated by alternative splicing (Kuhse et al., 1991). This subunit
is capable of forming functional homopentameric receptors in
vivo, which represent the embryonic and early postnatal form of
glycinergic neurotransmission. The embryonic configuration is
expressed throughout the nervous system and presumably located
extrasynaptically (Flint et al., 1998). Moreover, due to the embry-
onic chloride ion distribution over the cell membrane, the α2
homopentameric receptors display an excitatory mode of action
leading to a rise in intracellular calcium concentration (Flint et al.,
1998). GlyRα2 homomeric receptors display a lower agonist affin-
ity to glycine as compared to the α1 homopentamer. The potency
of the agonists glycine, β-alanine and taurine has been described
to be higher for the α2B variant (Miller et al., 2004). Mangin
et al. investigated the kinetic properties of the α2 homopen-
tameric GlyR at the single channel level. The homomeric α2
receptor type is slower by one or two orders of magnitude as com-
pared to the α1/β heteropentameric receptor involved in synaptic
glycinergic neurotransmission (Mangin et al., 2003). This was
reflected by a slow onset, relaxation and desensitization and a low
open probability upon synaptic-like application of glycine. These
physiological characteristics render the α2 homomeric receptor
inefficient for fast synaptic activation but comparatively suit-
able for activation via sustained and slow release of the agonist
(Mangin et al., 2003).
Making use of Glra2 knock-out mice the importance of this
specific GlyR subunit for neuronal development during embryo-
genesis as well as for normal CNS function during adulthood has
been investigated. First, there is no overt phenotype accompa-
nied by the loss of the α2 subunit. The knock-out mice resemble
normal weight compared to their wildtype littermates. Their
life expectancy is unchanged and fertility is also not affected in
the absence of the GlyRα2 subunit (Young-Pearse et al., 2006;
Weiss et al., 2008). Young-Pearse et al. have investigated poten-
tial morphological alterations upon knock-out of GlyRα2. No
striking abnormalities concerning the development and shape of
spinal cord, cortex and retina have been found. Diameter and cell
density of knock-out spinal cords were undistinguishable from
the wild type situation. Calcium uptake studies of embryonic
and neonatal cortical brain slices derived from knock-out ani-
mals confirmed the absence of functional GlyRs at that stage of
development. While glycine had no effect on calcium uptake,
stimulation by GABA induced a rise of intracellular calcium levels
confirming unaltered GABAergic activity. The loss of glyciner-
gic response was recovered at day P7 probably by expression of
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other GlyR subunits. However, despite the deficiency of elec-
trophysiological responses to GlyR agonists such as glycine and
taurine, the morphological development of cortices and cerebelli
in knock-out animals seems to be unaltered (Young-Pearse et al.,
2006).
In addition to its important role in brain stem and spinal
cord, glycine also acts, besides GABA, as an inhibitory neuro-
transmitter in the neuronal networks of the retina (Pourcho,
1996) where it has been found in 40–50% of all amacrine cells
(Marc, 1989). Within the variety of glycinergic amacrine cells,
all α-subunits have been identified in specific synapses (Sassoe-
Pognetto et al., 1994; Haverkamp et al., 2003, 2004; Heinze et al.,
2007). Immunoreactivity of the GlyRα2 subunit was found to be
evenly distributed across the inner plexiform layer representing
the most frequent type of GlyRs in this area (Haverkamp et al.,
2004).
Glra3 KNOCK-OUT MICE
The Glra3 gene encodes the GlyRα3 subunit, which can be found
within several regions of the CNS. Concerning its appearance in
the spinal cord, it is evenly distributed throughout the super-
ficial and deep laminae of the dorsal horn (Anderson et al.,
2009). With the help of immunhistochemical experiments Harvey
et al. could show that the GlyRα3 subunit can be co-stained pre-
dominantly in laminae II with gephyrin, which is necessary for
synaptic localization. Moreover, it could also be co-stained with
the α1 subunit of the GlyR, indicating that in these laminae II
both subunit-specific glycinergic synapses exist, which contain
either α1 or α3 and mixed synapses containing both α1 and α3.
Lamina II is the brain region where most nociceptive afferent
fibers terminate, which are involved in pain pathways (Harvey
et al., 2004). Concerning these pathways, following prostaglandin
E2 (PGE2) application a dramatic reduction in glycinergic inhi-
bition of neurons within the dorsal horn of rat spinal cord, the
first site of synaptic integration in the pain pathway was observed
(Ahmadi et al., 2002). In turn, PGE2 levels increase in the CNS
upon peripheral inflammation (Samad et al., 2001). First elec-
trophysiological experiments with human embryonic kidney cells
expressing the murine PGE2 receptor EP2 as well as the murine
GlyRα3 or a mutant lacking a PKA consensus sequence revealed
the putative mechanism of PGE2 activity via phosphorylation
and thereby inhibition of GlyRα3. It has been demonstrated that
GlyRα3 is selectively involved in spinal nociceptive processing.
During inflammatory pain states, PGE2 disinhibits via this mech-
anism the spinal transmission of nociceptive input throughout
the spinal cord dorsal horn to higher brain areas (Harvey et al.,
2004). This signal cascade leads to a sensitization of primary
afferents, thereby lowering thresholds for neuronal activation
and increasing nociceptor responsivity. The observed phenotype
results in increased responses to noxious stimulation termed
hyperalgesia, and allodynia where normally non-noxious stimuli
such as cooling, gentle touch, movement, and pressure are now
perceived as being painful (Harvey et al., 2009). Understanding
the role of GlyRα3 in pain processing pathways opened a new
therapeutic window to use the α3 subunit as a target for treatment
of chronic inflammatory pain. Ideally, therapeutic interventions
could selectively increase the activity of GlyRs containing α3,
which are down regulated via phosphorylation in inflammatory
pain. Therefore and to get more insights into pain pathways an
animal model was created: the Glra3 knock-out mouse (Harvey
et al., 2004).
Knock-out of the GlyRα3 subunit inmice, however, showed no
obvious phenotype and was compatible with life. These mice nor-
mally gain regular body weight and display no histopathological
abnormalities in brain and spinal cord. Moreover, no alterations
in posture, activity, gait, motor coordination, tremor, and star-
tle response have been observed (Harvey et al., 2004). Further
studies have been carried out to characterize GlyRα3 knock-out
mice concerning aspects of neurotransmission with regard to
the sensation of different kinds of pain. Chronic pain can be
broadly categorized into three types: inflammatory, neuropathic,
and dysfunctional. Inflammatory pain arises from tissue damage
and is associated with conditions such as arthritis. Neuropathic
pain can arise from trauma in peripheral or CNS as a conse-
quence of stroke or ischemia. The last type, dysfunctional pain,
is a type of neural dysfunction like migraine characterized by
a non-localized diffuse pain unaccompanied by either inflam-
mation or nerve damage (Harvey et al., 2009). Experiments
with α3 knock-out mice concerning the role of this GlyR sub-
unit in different pain pathways also show that the inhibition of
glycinergic neurotransmission by PGE2 does not contribute to
neuropathic pain after peripheral nerve injury. This supports the
idea that inflammatory and neuropathic pain involve different
mechanisms of central sensitization (Hosl et al., 2006). To get
more insights Harvey et al. investigated GlyRα3 and its potential
role in other clinically relevant pain models as well as in neu-
ropathic and visceral pain. GlyRα3−/− showed no difference in
the induction of thermal pain sensitization following CFA injec-
tion, but recovered much more quickly compared to the wild
type. Yet, there is no clear role in other inflammatory (treat-
ment with capsacin and carrageenan), neuropathic or visceral
pain models. Thus, GlyRα3 may play an important role in medi-
ating PGE2 induced sensitization, but only in certain pain states
(Harvey et al., 2009). Experiments concerning development of
GlyRα3 synapses contribute to previous findings. Any basal noci-
ceptive hypersensitivity is absent in GlyRα3−/−mice, but GlyRα1
is still available for mediating synaptic inhibition at lamina II
synapses but cannot be modulated by PGE2 signaling cascade
(Rajalu et al., 2009).
KNOCK-IN MOUSE MUTANTS
The approach of knock-in mice represents a powerful tool to look
for physiological effects in vivo (Crestani et al., 2001). Knock-
in mice have been generated to analyze the zinc modulation of
inhibitory neurotransmission, which has been attributed to sev-
eral residues in the N-terminus of GlyRα1 (Laube et al., 1995).
Zn2+ homeostasis is thought to be important for brain develop-
ment and function. Both, current responses of excitatory as well
as inhibitory ligand-gated ion channels have been shown to be
modulated by Zn2+ (Smart et al., 2004). Neutralization of aspar-
tate 80 (D80) with a glycine or alanine eliminated Zn2+ poten-
tiation of the glycine-gated responses (Lynch et al., 1998; Laube
et al., 2000). Homozygous mice carrying the D80A mutation dis-
played a neuromotor phenotype with an increased muscle tone
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and massive tremor around P12, which persisted into the adult-
hood similar to that observed for the spontaneous mouse mutants
spasmodic and spastic. In homozygous knock-in D80A mice
(Hirzel et al., 2006) the potentiating effect of Zn2+ on glycine-
gated currents recorded from cultured spinal cord neurons was
reduced but not abolished using low concentrations. High con-
centrations of Zn2+ did not affect glycinergic inhibition. The
residual Zn2+ potentiation observed in D80A knock-in mice may
be due to other GlyRs than the α1 subunit. Immunocytochemical
stainings showed massive labeling of extrasynaptic GlyRα2 argu-
ing for residual Zn2+ potentiation via nonsynaptic GlyRs (Laube
et al., 1995; Hirzel et al., 2006).
To study the pathomechanisms of human hyperekeplexia
in mice, Becker et al. introduced a human dominant muta-
tion tg271Q into the Glra1 gene (Becker et al., 2002). Binding
of the high affinity antagonist strychnine was unaffected, but
glycine affinity was reduced in spinal cord of tg271Q. Similarly,
in vitro studies on R271Q demonstrated decreased agonist affinity
accompanied with diminished glycine-gated currents (Langosch
et al., 1994; Rajendra et al., 1994). Whole-cell patch-clamp stud-
ies showed a decrease in glycinergic neurotransmission to 69%.
Interestingly, amplitudes of electrically evoked IPSCs from spinal
cord neurons were also reduced for GABAA-receptor-mediated
currents, which was not due to a lower level of GABAA receptor
expression. Transgenic animals developed spontaneous tremor
episodes from postnatal day 14 on with exaggerated startle
responses to noise or touch. These data showed for the first time
that a hyperekplexia-like phenotype is specific for the hyperek-
plexia associated mutated GlyR transgene. Besides the importance
of GlyRs for motor coordination, these receptors are also tar-
gets for ethanol, longer chain alcohols and anaesthetics. Ethanol
enhances glycine-gated responses and leads to loss of the right-
ing reflex (LORR) in mice (Findlay et al., 2002). This effect can
be antagonized with the glycine antagonist strychnine (Williams
et al., 1995). Several in vitro studies led to the identification of
distinct residues involved in ethanol potentiation (Mihic et al.,
1997). S267N located in the ion channel pore is one of the key
residues for ethanol modulation and has also been found in
patients that suffer from hyperekplexia (Becker et al., 2008). This
mutant displayed differences in agonist potency as well as ethanol
modulation and demonstrated that a disease-associated Glra1
mutation harbors the ability to alter drug responses. Similarly,
the potentiating effect of ethanol was highly diminished in S267N
knock-in mice. In contrast to the oscillator mutation, GlyRα1
protein expression in S267N knock-in animals was indistinguish-
able from wild-type levels. Glycine responses measured by uptake
of glycine-stimulated chloride uptake from synaptoneurosomes
from spinal cord and brainstem were decreased in heterozygous
animals but comparable to heterozygous oscillator mice (Findlay
et al., 2003). Muscimol-stimulated 36Cl− uptake was unchanged
arguing that GABAA receptor activity stayed unaffected. Thus,
GABAA receptors are not attributable for a compensatory effect
of the disturbed GlyR inhibition (Findlay et al., 2003). Behavioral
tests, however, displayed an enhanced acoustic startle response
(Findlay et al., 2005). Moreover, homozygous S267N knock-in
mice resulted in lethality 3 weeks after birth similar to the func-
tional null mutation (Kling et al., 1997; Findlay et al., 2003). This
observation provided the first evidence that a point mutation
does have a similar impact on the phenotype as the null allele.
Homology analysis with mutated GlyRs on the GLIC structure
searching for other amino acids, which are modulated by ethanol
came up with two more candidates Q266I and M287L (Blednov
et al., 2012; Borghese et al., 2012). Residue Q266 has also been
found in a patient suffering from hyperekplexia (Milani et al.,
1996). In knock-in mice both residues behave different to ethanol
modulation. M287L reduces ethanol potentiation whereas Q266I
abolished the ethanol potentiating effect. Physiological levels
of Zn2+ have been shown to enhance ethanol potentiation of
glycine-gated responses (McCracken et al., 2010). Although Zn2+
potentiation of glycine responses was unaffected, Zn2+ potenti-
ation of the ethanol response was abolished in M287L. Glycine-
induced maximal currents were reduced in isolated brain stem
neurons similar tomeasurements inXenopus oocytes. In addition,
ethanol potentiation was absent in brainstem neurons isolated
from homozygous knock-in mice. Radioligand binding assays
demonstrated a reduced displacement of glycine by strychnine
for knock-in animals, but flunitrazepam binding was not affected
similar to previous findings in S267N knock-in mice (Borghese
et al., 2012). These data again argue for lack of GABAergic
compensation in GlyR-deficient mouse models. Behavioral char-
acterization demonstrated an enhanced acoustic startle response
for both mutants Q266I andM287L as observed for S267N, which
is a hallmark for disturbances in glycinergic inhibition (Findlay
et al., 2005; Blednov et al., 2012). A progressive phenotype start-
ing from postnatal day 10 with massive muscle tremor and loss of
motor control resulted in lethality between the 3 (Q266I) and 14
weeks (M287L) of life.
RECEPTOR ASSEMBLY FROM INDEPENDENTLY FOLDING
DOMAINS
Receptor domains display high homology to other kinds of
proteins, which exhibit different functions in their natural sur-
rounding. The N-terminal part of CLRs for example shows high
homology to the AchBP from the snail Lymnea stagnalis(Brejc
et al., 2001). Similarly, the excitatory glutamate receptors repre-
sent a mosaic with homology of the ligand binding domains to
bacterial periplasmic binding proteins (LAOBP, lysine-arginine-
ornithine binding protein and LIVBP, leucine-isoleucine-valine
binding proteins). LIVBP homology has been found in the far
N-terminal domain of GluRs important for receptor assembly. In
addition, the pore domain represents high homology to the ion
channel domain of K+ channels (Villmann and Becker, 2007).
Several studies on domain swapping have shown that homol-
ogous domains can be exchanged between different receptor
subclasses without dramatic changes in ion channel properties
(Strutz et al., 2002; Hoffmann et al., 2006; Villmann et al.,
2008). Reconstitution of functionality from independent folding
domains seemed to be a chance to gain-of-function for trun-
cated receptor proteins. The mouse mutant oscillator was used
as a model system since the underlying mutation, a microdele-
tion, results in a premature STOP codon. This mouse mutant
represents a functional null allele (Kling et al., 1997). In vitro
experiments demonstrated that the coexpression of truncated
receptor protein together with an independent “tail” construct
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representing the lacking proportion of the GlyRα1 protein, most
of the TM3-4 loop, TM4, and the C-terminus rescued the GlyR
function to about 10–50% of wild type activity. An infection of
spinal cord neurons isolated from homozygous oscillator mice
with an adeno-associated viral vector encoding the independent
tail construct induced an expression of the α1 antigen compared
to uninfected cells lacking α1 expression (Figure 4) (Villmann
et al., 2009a).
This view on GlyR assembly from different folding domains
toward a functional receptor will be a useful tool for restoration
of ion channel function in other kinds of diseases such as the idio-
pathic generalized epilepsies, where mutations in genes encoding
the postsynaptic inhibitory GABAA receptor subunits resulting in
protein truncation have been identified.
POSSIBLE ROUTES OF COMPENSATION
Mutations in GlyR genes Glra1 and Glrb result in a neuromotor
phenotype similar to patients suffering from hyperekplexia. That
is why mice serve as excellent models for this human neuromo-
tor disorder. The variety of mutations in mice comprises point
mutations, microdeletions, duplications, and insertions. Human
patients usually get treated with clonazepam, which helps via an
enhancement of GABAergic responses to compensate for the lack
or decrease of glycinergic inhibition. Although GABAergic com-
pensation is also favored in mice, different experiments failed
to show GABAergic upregulation at the level of expression. No
changes in radioligand binding studies using brainstem or spinal
cord membrane preparation from tissue have been observed
meaning that the number of GABAA receptors expressed in these
membranes is unchanged (Becker et al., 2002; Blednov et al.,
2012). Pharmacological studies on knock-in mice demonstrated
that GABAA receptor modulators such as flurazepam and pento-
barbital induced an increase in LORR in addition to an increase
in GlyR sensitivity to pentobarbital. Also picrotoxin-induced con-
vulsions differed in knock-in mice suggesting changes in GABAA
receptor function (Blednov et al., 2012). An enhancement of
GABAergic maximal current amplitudes has been shown in spas-
tic mice, but in knock-in mice no functional differences were
observed for GABAA receptors (White and Heller, 1982; Findlay
et al., 2003). Other compensatory effects via nAChR or NMDA
receptors analyzed by ketamine or ethanol action used in behav-
ioral studies of GlyR knock-in mice are difficult to interpret
as these modulators at various concentrations act also directly
on these classes of ligand-gated ion channels. What we have
learned from knock-in mice is that there is very limited or no
compensation. Moreover, in vitro studies on a human mutation
with moderate effects on GlyR functionality could result in a
severe impairment of glycinergic neurotransmission associated by
lethality in vivo.
For the spontaneous mutations affecting one of the GlyR
subunits present in the adult receptor complex, α1 or β, compen-
satory mechanisms have been described in detailed physiological
recordings. The rise and decay times of mIPSCs were simi-
lar between spa/spa and controls. Therefore, changes in GlyR
distribution seem unlikely, but the lower frequency is in line
with less α1β clusters due to lower transcription rate of full-
length β subunits. Compensation in spa/spa via homomeric α1
was favored as one possible mechanism; however, such homo-
meric α1 receptors have never been observed at synaptic sites
(Graham et al., 2006). As a consequence of low GlyRβ numbers
at the postsynaptic side in spastic mice, glycinergic presynaptic
terminals decrease demonstrating an adaption process the sec-
ond postnatal week (Muller et al., 2008). Recently, Becker et al.
have demonstrated that mouse line background could also have
a compensatory effect on the appearance of the spastic pheno-
type. In addition to the insertion of a LINE1 element in intron
6 of the Glrb gene resulting in changes in endogenous splicing,
a SNP in exon 6 functions as an ESE important for binding
of the splice factor SRSF1. Minigene experiments showed that
mis-splicing of the β-subunit could be rescued by the A/G transi-
tion in exon 6 present in the C3H/HeJ mouse background but
absent in C57BL/6J where the spastic mutation was originally
described (Becker et al., 2012). In ot/ot animals slow mIPSCs
with very low amplitudes suggest some remaining GlyR clus-
ters present at distal dendritic locations. Although the expression
of α2, α3, and α4 in oscillator is normal, the compensatory
GlyR clusters are not sufficient to sustain life (Graham et al.,
2006). In summary, some sort of compensation seem to exist in
various mouse models for hyperekplexia, but neither upregula-
tion of GABAergic responses nor compensation by other GlyR
subunits are able to rescue glycinergic dysfunction in mouse
spinal cord. Thus, disturbances in glycinergic inhibition perturb
a neuronal network with the GlyR playing a key role in this
network.
CONCLUSIONS
Functional inhibitory GlyRs are important for neuromotor
behavior. Disturbances in the glycinergic synaptic circuit lead to
severe startle reactions in response to tactile or acoustic stim-
uli. Spontaneous mutations and knock-in mice carrying human
hyperekplexia mutations serve as models to understand the
human neuromotor phenotype. But why do some mutations in
the GlyR genes (Glra1 or Glrb) in rodents result in a mild and
others in a lethal phenotype? Are there differences in compen-
satory mechanisms? The strength of a phenotype could result
from mouse line background as recently shown for the two hit
splice mutation in the mouse mutant spastic. Furthermore, the
functional effect depends on the location of the mutation. Here,
the increasing knowledge on the molecular structure of CLRs
during the last decade opened novel windows for an interpre-
tation of functional data with the help of homologous models.
Interestingly, knock-out mice of the GlyRα2 or α3 demonstrated
normal life span. In contrast, the functional null allele of the
Glra1 gene resulted in lethality at the age of 3 weeks when the
developmental shift toward the adult receptor complex α1β is
completed. Therefore, there is no doubt that heteromeric α1β
GlyRs play themost important role for fast inhibitory neurotrans-
mission processes inmotor function. So far premature truncation
of GlyRα1 could only be compensated when the lacking pro-
tein proportion was coexpressed at least in vitro. An assembly
of functional GlyRs from independent domains seems to over-
come processes like nonsense-mediated decay or when translated
ER-mediated degradation. But the existence of similar coordi-
nated assembly processes in vivo has to be proven. According
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to the human mutations, all described GlyRα1 knock-in stud-
ies exhibited similar functional differences on GlyRs compared
to in vitro data obtained from either transfected cell lines or
oocyte recordings. Thus, mice seem to be an excellent model
system to study hyperekplexia. Mice carrying human mutations
showed an onset of symptoms as massive tremor and startle
attacks with the age of 15 days when developmental changes
in GlyR subunit composition are almost completed. Treatment
of human patients with clonazepam favored an up-regulation
of the GABAergic neurotransmission. Therefore, most studies
looking for compensatory mechanisms in mice concentrated on
the receptor configuration at the postsynaptic side. All physio-
logical studies so far have, however, strikingly shown that the
central role of the adult isoform α1β cannot be compensated
by another GlyR receptor configuration neither by α3β, homo-
meric α1, α2 nor distinct GABAA receptors. Although there is
still requirement to search for subunit-specific blockers of either
α1, or α2, or α3, and β, to improve the interpretation of phys-
iological data, our knowledge on the differences in the kinetics
of GlyR subpopulations has amazingly increased during the last
years. Yet, the complexity of synaptic circuits in vivo as well
as synaptic adaption processes are far away from being under-
stood. One future direction of research is trying to identify so
far unknown regulatory elements or proteins responsible for
synaptic adaptation at the inhibitory synapses during glyciner-
gic disturbances. It has been shown that presynaptic terminals
and postsynaptic elements communicate with, e.g., an adapta-
tion of less presynaptic glycinergic terminals in response to less
GlyRβ at the postsynapse in themouse mutant spastic. GABAergic
terminals instead increase but GABAA receptor numbers stay
unaffected. The various mouse models discussed here demon-
strate that the current hypothesis of GABAergic compensation
for a failure in glycinergic neurotransmission has to be care-
fully scrutinized. An enhancement of the GABAergic responses
by treatment with clonazepam is therefore unlikely to explain
the massive improvement of symptoms observed in human
patients. Thus, the described mouse models in combination with
modern imaging techniques and proteomics serve as excellent
tools to close the gap between adaptation and remodeling of
inhibitory synapses in vivo under physiological and pathological
conditions.
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